Lutetium-177 PSMA Radioligand Therapy Improves Disease Control but Not Yet Overall Survival in mCRPC: A Critical Appraisal of a Six‑RCT Meta-Analysis
A meta-analysis of six randomized trials shows [177Lu]Lu‑PSMA significantly increases PSA and objective responses and reduces risk of radiographic progression, with no significant increase in high‑grade toxicity and no clear overall survival benefit to date.